Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
J Clin Pharm Ther 2012;
38:175-6. [PMID:
23210935 DOI:
10.1111/jcpt.12031]
[Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2011] [Accepted: 10/31/2012] [Indexed: 01/12/2023]
Abstract
WHAT IS KNOWN AND OBJECTIVE
Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC).
CASE SUMMARY
A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib.
WHAT IS NEW AND CONCLUSION
There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
Collapse